EarningsQ2 2026 Earnings Report
DE:6OM Q2 2026 EPS Results
Actual EPS-€0.17
Consensus EPS-€0.07
Beat/MissMissed by -€0.09
One Year Ago EPS€0.23
DE:6OM Q2 2026 Revenue Results
Actual Revenue€547.25M
Expected Revenue€561.02M
Beat/MissMissed by -€13.76M
YoY Revenue Growth-10.07%
Earnings Announcement Details
QuarterQ2 2026
Date08/10/2026
TimeBefore Open
Conference CallMonday, August 10, 2026
DE:6OM Upcoming Earnings
Accendra Health's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:6OM Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlighted meaningful strategic and financial progress — notably >$125M of annualized cost reductions, a successful balance sheet optimization (debt down ~ $400M and extended maturities), improving growth in sleep and diabetes, and commercial wins and operational initiatives positioned to drive late‑2026/2027 upside. However, near‑term performance was impaired by several material operational headwinds: unusually large payor audit activity that depressed collections (≈$10M in Q2, $20M H1), worsening AR and cash pressure, category weakness in respiratory and wound, and later-than-expected timing of cost benefits. Management has clear remediation plans (cost actions, collections fixes, logistics partnerships, asset sales, ATM program) and expects a stronger Q4 and improved 2027, but the near-term mix of execution and cash challenges tempers the positive long‑term narrative.Company Guidance
Cost Reduction Actions
Identified and eliminated more than $125 million of annualized costs; additional targeted cost reductions executed ~1 month into Q3 and more opportunities under evaluation to streamline operations and reduce cost to serve.
Balance Sheet Optimization and Debt Reduction
Completed balance sheet optimization in June: total debt reduced to $1.72 billion (down ~ $400 million since end of March), net debt > $55 million lower, weighted average life of debt extended to ~5.5 years with no maturities until 2029.
Revenue Growth Momentum in Key Categories
On a like-for-like basis (excluding the large commercial payor exit) total revenue grew 2% in Q2. Sleep category improved with ~5.5% year-over-year growth (marked improvement in sleep equipment and strong supplies growth). Diabetes grew 4% (a 500 bps improvement vs Q1). Ostomy and Urology delivered high-single-digit growth.
Adjusted EBITDA and Capital Deployment
Reported Q2 adjusted EBITDA just over $60 million; adjusted EBITDA less patient service equipment (PSE CapEx) was $16.3 million. Company expects full-year 2026 adjusted EBITDA of $300 million to $320 million and free cash flow (fully levered) to be breakeven to slightly positive for 2026.
Commercial and Strategic Wins
Renewed largest soft goods contract with largest commercial payor (signed in Q2), signed a new sole-source agreement with a regional health system (expected launch early 2027), and executed an enterprise-wide fee-for-service agreement expected to drive additional patient volume and capacity utilization.
Operational Initiatives to Drive Future Growth
Advancing national rollout of Sleep Center of Excellence (expected to contribute to growth and profitability beginning late 2026 into 2027); pursuing logistics partnerships to improve inventory management, lower operating cost and improve cash flow; continued investment in technology and automation.
Noncore Asset Sales and Liquidity Actions
Closed sale of a small noncore asset in July with another expected in late Q3/early Q4; company plans a small at-the-market (ATM) equity program to reduce indebtedness and implement an NOL rights plan to protect tax attributes (net operating loss carryforwards expected > $200 million going into 2027).
Leadership Succession Planning
CEO announced intention to retire by end of 2026; management and Board emphasize a long-standing succession planning process and intention for an orderly transition.
DE:6OM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed